The upper cervical spinal cord in ALS assessed by cross-sectional and longitudinal 3T MRI.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
04 02 2020
Historique:
received: 23 10 2019
accepted: 20 01 2020
entrez: 6 2 2020
pubmed: 6 2 2020
medline: 18 11 2020
Statut: epublish

Résumé

The upper cervical spinal cord is measured in a large longitudinal amyotrophic lateral sclerosis (ALS) cohort to evaluate its role as a biomarker. Specifically, the cervical spinal cord´s cross-sectional area (CSA) in plane of the segments C1-C3 was measured semi-automatically with T1-weighted 3T MRI sequences in 158 ALS patients and 86 controls. Six-month longitudinal follow-up MRI scans were analyzed in 103 patients. Compared to controls, in ALS there was a significant mean spinal cord atrophy (63.8 mm² vs. 60.8 mm², p = 0.001) which showed a trend towards worsening over time (mean spinal cord CSA decrease from 61.4 mm² to 60.6 mm² after 6 months, p = 0.06). Findings were most pronounced in the caudal segments of the upper cervical spinal cord and in limb-onset ALS. Baseline CSA was related to the revised ALS functional rating scale, disease duration, precentral gyrus thickness and total brain gray matter volume. In conclusion, spinal cord atrophy as assessed in brain MRIs in ALS patients mirrors the extent of overall neurodegeneration and parallels disease severity.

Identifiants

pubmed: 32020025
doi: 10.1038/s41598-020-58687-z
pii: 10.1038/s41598-020-58687-z
pmc: PMC7000761
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1783

Références

Goetz, C. G. Amyotrophic lateral sclerosis: early contributions of Jean-Martin Charcot. Muscle Nerve 23, 336–343; 10.1002/(sici)1097-4598(200003)23: 3<336::aid-mus4>3.0.co;2-l (2000).
doi: 10.1002/(SICI)1097-4598(200003)23:3<336::AID-MUS4>3.0.CO;2-L
Brettschneider, J. et al. TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. Acta Neuropathol 128, 423–437, https://doi.org/10.1007/s00401-014-1299-6 (2014).
doi: 10.1007/s00401-014-1299-6 pubmed: 24916269 pmcid: 4384652
Brettschneider, J. et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 74, 20–38, https://doi.org/10.1002/ana.23937 (2013).
doi: 10.1002/ana.23937 pubmed: 23686809 pmcid: 3785076
Geser, F. et al. Motor neuron disease clinically limited to the lower motor neuron is a diffuse TDP-43 proteinopathy. Acta Neuropathol 121, 509–517, https://doi.org/10.1007/s00401-011-0797-z (2011).
doi: 10.1007/s00401-011-0797-z pubmed: 21225272 pmcid: 3125638
Agosta, F. et al. A longitudinal diffusion tensor MRI study of the cervical cord and brain in amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry 80, 53–55, https://doi.org/10.1136/jnnp.2008.154252 (2009).
doi: 10.1136/jnnp.2008.154252 pubmed: 18931009
Cohen-Adad, J. et al. Involvement of spinal sensory pathway in ALS and specificity of cord atrophy to lower motor neuron degeneration. Amyotrophic lateral sclerosis & frontotemporal degeneration 14, 30–38, https://doi.org/10.3109/17482968.2012.701308 (2013).
doi: 10.3109/17482968.2012.701308
Cohen-Adad, J. et al. 7-T MRI of the spinal cord can detect lateral corticospinal tract abnormality in amyotrophic lateral sclerosis. Muscle Nerve 47, 760–762, https://doi.org/10.1002/mus.23720 (2013).
doi: 10.1002/mus.23720 pubmed: 23553571
Branco, L. M. T. et al. Spinal cord atrophy correlates with disease duration and severity in amyotrophic lateral sclerosis. Amyotroph Lat. Scl. Fr. 15, 93–97, https://doi.org/10.3109/21678421.2013.852589 (2014).
doi: 10.3109/21678421.2013.852589
Paquin, M.-Ê. et al. Spinal Cord Gray Matter Atrophy in Amyotrophic Lateral Sclerosis. AJNR. American journal of neuroradiology 39, 184–192, https://doi.org/10.3174/ajnr.A5427 (2018).
doi: 10.3174/ajnr.A5427 pubmed: 29122760
Valsasina, P. et al. Diffusion anisotropy of the cervical cord is strictly associated with disability in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 78, 480–484, https://doi.org/10.1136/jnnp.2006.100032 (2007).
doi: 10.1136/jnnp.2006.100032 pubmed: 17030586
Olney, N. T. et al. Measurement of spinal cord atrophy using phase sensitive inversion recovery (PSIR) imaging in motor neuron disease. PLoS One 13, e0208255, https://doi.org/10.1371/journal.pone.0208255 (2018).
doi: 10.1371/journal.pone.0208255 pubmed: 30496320 pmcid: 6264489
El Mendili, M. M. et al. Multi-parametric spinal cord MRI as potential progression marker in amyotrophic lateral sclerosis. PLoS One 9, e95516, https://doi.org/10.1371/journal.pone.0095516 (2014).
doi: 10.1371/journal.pone.0095516 pubmed: 24755826 pmcid: 3995720
Albuquerque, M. et al. Longitudinal evaluation of cerebral and spinal cord damage in Amyotrophic Lateral Sclerosis. Neuroimage Clin 14, 269–276, https://doi.org/10.1016/j.nicl.2017.01.024 (2017).
doi: 10.1016/j.nicl.2017.01.024 pubmed: 28203530 pmcid: 5294732
Brooks, B. R., Miller, R. G., Swash, M. & Munsat, T. L. El Escorial revisited. Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Sc 1, 293–299, https://doi.org/10.1080/146608200300079536 (2000).
doi: 10.1080/146608200300079536
Brooks, B. R. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J. Neurol Sci 124, 96–107, 10.1016/0022-510×(94)90191-0(1994).
doi: 10.1016/0022-510X(94)90191-0
Carvalho, M. et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 119, 497–503 (2008).
doi: 10.1016/j.clinph.2007.09.143
Schreiber, S. et al. Peripheral nerve ultrasound in amyotrophic lateral sclerosis phenotypes. Muscle Nerve 51, 669–675, https://doi.org/10.1002/mus.24431 (2015).
doi: 10.1002/mus.24431 pubmed: 25155020
van den RM, B.-V. et al. The spectrum of lower motor neuron syndromes. J Neurol 250, 1279–1292 (2003).
doi: 10.1007/s00415-003-0235-9
van den RM, B.-V. et al. Sporadic lower motor neuron disease with adult onset. Classification of subtypes. Brain 126, 1036–1047 (2003).
doi: 10.1093/brain/awg117
Soraru, G. et al. Natural history of upper motor neuron-dominant ALS. Amyotroph. Lateral. Scler. 11, 424–429 (2010).
doi: 10.3109/17482960903300867
Gordon, P. H., Cheng, B., Katz, I. B., Mitsumoto, H. & Rowland, L. P. Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS. Neurology 72, 1948–1952 (2009).
doi: 10.1212/WNL.0b013e3181a8269b
Al-Chalabi, A. et al. Amyotrophic lateral sclerosis: moving towards a new classification system. The Lancet Neurology 15, 1182–1194, https://doi.org/10.1016/S1474-4422(16)30199-5 (2016).
doi: 10.1016/S1474-4422(16)30199-5 pubmed: 27647646
Finegan, E., Chipika, R. H., Shing, S. L. H., Hardiman, O. & Bede, P. Primary lateral sclerosis: a distinct entity or part of the ALS spectrum? Amyotrophic lateral sclerosis & frontotemporal degeneration 20, 133–145, https://doi.org/10.1080/21678421.2018.1550518 (2019).
doi: 10.1080/21678421.2018.1550518
Gordon, P. H. et al. The natural history of primary lateral sclerosis. Neurology 66, 647–653 (2006).
doi: 10.1212/01.wnl.0000200962.94777.71
Tartaglia, M. C. et al. Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis. Examination of symptoms and signs at disease onset and during follow-up. Arch. Neurol. 64, 232–236 (2007).
doi: 10.1001/archneur.64.2.232
Rascovsky, K. et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134, 2456–2477 (2011).
doi: 10.1093/brain/awr179
Prell, T. et al. Assessment of pulmonary function in amyotrophic lateral sclerosis: when can polygraphy help evaluate the need for non-invasive ventilation? J Neurol Neurosurg Psychiatry 87, 1022–1026, https://doi.org/10.1136/jnnp-2015-312185 (2016).
doi: 10.1136/jnnp-2015-312185 pubmed: 27010615 pmcid: 5013137
Andersen, P. M. et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)–revised report of an EFNS task force. Eur J. Neurol. 19, 360–375, https://doi.org/10.1111/j.1468-1331.2011.03501.x (2012).
doi: 10.1111/j.1468-1331.2011.03501.x pubmed: 21914052
Machts, J. et al. Basal ganglia pathology in ALS is associated with neuropsychological deficits. Neurology 85, 1301–1309, https://doi.org/10.1212/WNL.0000000000002017 (2015).
doi: 10.1212/WNL.0000000000002017 pubmed: 26385880
Schreiber, S. et al. Significance of CSF NfL and tau in ALS. J Neurol 265, 2633–2645, https://doi.org/10.1007/s00415-018-9043-0 (2018).
doi: 10.1007/s00415-018-9043-0 pubmed: 30187162
Bergo, F. P. G., França, M. C., Chevis, C. F. & Cendes, F. SpineSeg: A segmentation and measurement tool for evaluation of spinal cord atrophy. 7th Iberian Conference on Information Systems and Technologies (CISTI 2012) pp. 1–4 (2012).
Bergo, F. P. G., Falcão, A. X., Miranda, P. A. V. & Rocha, L. M. Automatic Image Segmentation by Tree Pruning. Journal of Mathematical Imaging and Vision 29, 141–162, https://doi.org/10.1007/s10851-007-0035-4 (2007).
doi: 10.1007/s10851-007-0035-4
Fischl, B. et al. Whole Brain Segmentation. Neuron 33, 341–355, https://doi.org/10.1016/S0896-6273(02)00569-X (2002).
doi: 10.1016/S0896-6273(02)00569-X
Kameyama, T., Hashizume, Y. & Sobue, G. Morphologic features of the normal human cadaveric spinal cord. Spine 21, 1285–1290 (1996).
doi: 10.1097/00007632-199606010-00001
Turner, M. R. et al. The diagnostic pathway and prognosis in bulbar-onset amyotrophic lateral sclerosis. J. Neurol. Sci. 294, 81–85, https://doi.org/10.1016/j.jns.2010.03.028 (2010).
doi: 10.1016/j.jns.2010.03.028 pubmed: 20452624
Sperfeld, A.-D. et al. MR-pathologic comparison of the upper spinal cord in different motor neuron diseases. Eur. Neurol. 53, 74–77, https://doi.org/10.1159/000084650 (2005).
doi: 10.1159/000084650 pubmed: 15785072
Losseff, N. A. et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 119(Pt 3), 701–708, https://doi.org/10.1093/brain/119.3.701 (1996).
doi: 10.1093/brain/119.3.701 pubmed: 8673483

Auteurs

Thomas Wimmer (T)

Department of Neurology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.

Frank Schreiber (F)

Department of Neurology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
German Center for Neurodegenerative Diseases, Magdeburg Site, Magdeburg, Germany.

Nathalie Hensiek (N)

Department of Neurology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.

Cornelia Garz (C)

Department of Neurology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
German Center for Neurodegenerative Diseases, Magdeburg Site, Magdeburg, Germany.
Leibniz Institute for Neurobiology (LIN), Magdeburg, Germany.

Jörn Kaufmann (J)

Department of Neurology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.

Judith Machts (J)

Department of Neurology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
German Center for Neurodegenerative Diseases, Magdeburg Site, Magdeburg, Germany.

Susanne Vogt (S)

Department of Neurology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.

Johannes Prudlo (J)

Department of Neurology, University Medical School Rostock, Rostock, Germany.
German Center for Neurodegenerative Diseases, Rostock Site, Rostock, Germany.

Reinhard Dengler (R)

Department of Neurology, Hannover Medical School, Hannover, Germany.

Susanne Petri (S)

Department of Neurology, Hannover Medical School, Hannover, Germany.

Hans-Jochen Heinze (HJ)

Department of Neurology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
German Center for Neurodegenerative Diseases, Magdeburg Site, Magdeburg, Germany.
Leibniz Institute for Neurobiology (LIN), Magdeburg, Germany.
Center for Behavioral Brain Sciences (CBBS), Magdeburg, Germany.

Peter J Nestor (PJ)

Queensland Brain Institute, The University of Queensland, Brisbane, Australia.
Mater Hospital, Brisbane, Australia.

Stefan Vielhaber (S)

Department of Neurology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
German Center for Neurodegenerative Diseases, Magdeburg Site, Magdeburg, Germany.
Center for Behavioral Brain Sciences (CBBS), Magdeburg, Germany.

Stefanie Schreiber (S)

Department of Neurology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany. stefanie.schreiber@med.ovgu.de.
German Center for Neurodegenerative Diseases, Magdeburg Site, Magdeburg, Germany. stefanie.schreiber@med.ovgu.de.
Center for Behavioral Brain Sciences (CBBS), Magdeburg, Germany. stefanie.schreiber@med.ovgu.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH